Gene therapy of cancer with interferon: Lessons from tumor models and perspectives for clinical applications

Seminars in Cancer Biology

Volumn 10, Issue 2, 2000, Pages 145-157

  Ferrantini, Maria ^a   Belardelli, Filippo ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Cancer; Gene therapy; Interferon

Indexed keywords

ALPHA INTERFERON; GANCICLOVIR; INTERFERON; PRODRUG;

CANCER; CANCER COMBINATION CHEMOTHERAPY; CARCINOGENESIS; GENE TECHNOLOGY; GENE THERAPY; HUMAN; INTERFERON INDUCTION; INTERFERON PRODUCTION; NONHUMAN; PROTEIN EXPRESSION; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 0033941331     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1006/scbi.2000.0333     Document Type: Article

References (101)

1. Gutterman J U. Cytokine therapeutics: Lessons from interferon α Proc Natl Acad Sci USA. 91:1994;1198-1205.
2. Belardelli F. Role of interferons and other cytokines in the regulation of the immune response. APMIS. 103:1995;161-179.
3. Pfeffer L M, Dinarello C A, Herberman R B, Williams BR G, Borden E C, Bordens R, Walter M R, Nagabhushan T L, Trotta P P, Pestka S. Biological properties of recombinant α -interferons: 40th anniversary of the discovery of interferons. Cancer Res. 58:1998;2489-2499.
4. Hussein A M. The potential application of gene transfer in the treatment of patients with cancer: a concise review. Cancer Invest. 14:1996;343-352.
5. Musiani P, Modesti A, Giovarelli M, Cavallo F, Colombo M P, Lollini P L, Forni G. Cytokines, tumor-cell death, and immunogenicity: a question of choice. Immunol Today. 18:1997;32-36.
6. Pardoll D M. Cancer vaccines. Nat Med. 4:1998;525-531.
7. Watanabe Y, Kuribayashi K, Miyatake S, Nishihara K, Nakayama E, Taniyama T, Sakata T. Exogenous expression of mouse interferon γ cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented antitumor immunity. Proc Natl Acad Sci USA. 86:1989;9456-9460.
8. Gansbacher B, Bannerji R, Daniels B, Zier K, Cronin K, Gilboa E. Retroviral vector-mediated γ -interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res. 50:1990;7820-7825.
9. Esumi N, Hunt B, Itaya T, Frost P. Reduced tumorigenicity of murine tumor cells secreting γ -interferon is due to nonspecific host responses and is unrelated to class I major histocompatibility complex expression. Cancer Res. 51:1991;1185-1189.
10. Lollini P L, Bosco M C, Cavallo F, De Giovanni C, Giovarelli M, Landuzzi L, Musiani P, Modesti A, Nicoletti G, Palmieri G, Santoni A, Young H A, Forni G, Nanni P. Inhibition of tumor growth and enhancement of metastasis after transfection of the γ -interferon gene. Int J Cancer. 55:1993;320-329.
11. Musiani P, Allione A, Modica A, Lollini P L, Giovarelli M, Cavallo F, Belardelli F, Forni G, Modesti A. Role of neutrophils and lymphocytes in inhibition of a mouse mammary adenocarcinoma engineered to release IL-2, IL-4, IL-7, IL-10, IFN- α, IFN- γ, and TNF- α Lab Invest. 74:1996;146-157.
12. Porgador A, Bannerji R, Watanabe Y, Feldman M, Gilboa E, Eisenbach L. Antimetastatic vaccination of tumor-bearing mice with two types of IFN- γ gene-inserted tumor cells. J Immunol. 150:1993;1458-1470.
13. Porgador A, Tzehoval E, Vadai E, Feldman M, Eisenbach L. Immunotherapy via gene therapy: comparison of the effects of tumor cells transduced with the interleukin-2, interleukin-6, or interferon- γ genes. J Immunother. 14:1993;191-201.
14. Hock H, Dorsch M, Kunzendorf U, Qin Z, Diamantstein T, Blankestein T. Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon γ Proc Natl Acad Sci USA. 90:1993;2774-2778.
15. Xu X, Dai Y, Heidenreich O, Nerenberg M I. Adenovirus-mediated interferon- γ transfer inhibits growth of transplanted HTLV-1 tax tumors in mice. Hum Gene Ther. 7:1996;471-477.
16. kand concomitant enhanced metastasis. Cancer Immunol Immunother. 42:1996;329-338.
17. Kawakita M, Rao G S, Ritchey J K, Ornstein D K, Hudson M'L A, Tartaglia J, Paoletti E, Humphrey P A, Harmon T J, Ratliff T L. Effect of canarypox virus (ALVAC)-mediated cytokine expression on murine prostate tumor growth. J Natl Cancer Inst. 89:1997;428-436.
18. Raes G, Geldhof A, Vanden Driessche T, Opdenakker G, Sibille G, De Baetselier P. Immunogenization of a murine T-cell lymphoma via transfection with interferon-gamma. Leukemia. 9 (Suppl 1):1995;S121-127.
19. Rosenthal F M, Cronin K, Bannerji R, Golde D W, Gansbacher B. Augmentation of antitumor immunity by tumor cells transduced with a retroviral vector carrying the interleukin-2 and interferon- γ cDNAs. Blood. 83:1994;1289-1298.
20. McAdam A J, Pulaski B A, Harkins S S, Hutter E K, Lord E M, Frelinger J G. Synergistic effects of co-expression of the Th1 cytokines IL-2 and IFN- γ on generation of murine tumor-reactive cytotoxic cells. Int J Cancer. 61:1995;628-634.
21. Lollini P L, De Giovanni C, Landuzzi L, Nicoletti G, Frabetti F, Cavallo F, Giovarelli M, Forni G, Modica A, Modesti A, Musiani P, Nanni P. Transduction of genes coding for a histocompatibility (MHC) antigen and for its physiological inducer interferon- γ in the same cell: efficient MHC expression and inhibition of tumor and metastasis growth. Hum Gene Ther. 6:1995;743-752.
22. Hurwitz A A, Townsend S E, Yu TF Y, Wallin J A, Allison J P. Enhancement of the antitumor immune response using a combination of interferon- γ and B7 expression in an experimental mammary carcinoma. Int J Cancer. 77:1998;107-113.
23. Tanaka H, Yoshizawa H, Yamaguchi Y, Ito K, Kagamu H, Suzuki E, Gejyo F, Hamada H, Arakawa M. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells. J Immunol. 162:1999;3574-3582.
24. Belardelli F, Gresser I. The neglected role of type I interferon in the T-cell response: implications for its clinical use. Immunol Today. 17:1996;369-372.
25. Belardelli F, Gresser I, Maury C, Maunoury M T. Antitumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant Friend leukemia cells. II. Role of host mechanisms. Int J Cancer. 31:1982;821-825.
26. Gresser I, Maury C, Woodrow D, Moss J, Grütter M G, Vignaux F, Belardelli F, Maunoury M T. Interferon treatment markedly inhibits the development of tumor metastases in the liver and spleen and increases survival time of mice after intravenous inoculation of Friend erythroleukemia cells. Int J Cancer. 41:1988;135-142.
27. Gresser I, Carnaud C, Maury C, Sala A, Eid P, Woodrow D, Maunoury M T, Belardelli F. Host humoral and cellular mechanisms in the continued suppression of Friend erythroleukemia metastases after interferonα / β treatment in mice. J Exp Med. 173:1991;1193-1203.
28. Ferrantini M, Proietti E, Santodonato L, Gabriele L, Peretti M, Plavec I, Meyer F, Kaido T, Gresser I, Belardelli F. Alpha1-interferon gene transfer into metastatic Friend leukemia cells abrogated tumorigenicity in immunocompetent mice: Antitumor therapy by means of interferon-producing cells. Cancer Res. 53:1993;1107-1112.
29. Gabriele L, Kaido T, Woodrow D, Moss J, Ferrantini M, Proietti E, Santodonato L, Rozera C, Maury C, Belardelli F, Gresser I. The local and systemic response of mice to interferon- α 1 transfected Friend Leukemia cells. Am J Pathol. 147:1995;445-460.
30. +T cell-mediated tumor rejection and development of antitumor immunity. Comparative studies with IFN-gamma producing TS/A cells. J Immunol. 153:1994;4604-4615.
31. Tüting T, Gambotto A, Baar J, Storkus W J, Zavodny P J, Narula S, Tahara H, Robbins P D, Lotze M T. Interferon- α gene therapy for cancer: retroviral transduction of fibroblasts and particle-mediated transfection of tumor cells are both effective strategies for gene delivery in murine tumor models. Gene Ther. 4:1997;1053-1060.
32. Kaido T, Bandu M T, Maury C, Ferrantini M, Belardelli F, Gresser I. IFN- α 1 gene transfection completely abolishes the tumorigenicity of murine B16 melanoma cells in allogeneic DBA/2 mice and decreases their tumorigenicity in syngeneic C57BL/6 mice. Int J Cancer. 60:1995;1-9.
33. Sarkar S, Flores I, De Rosa C, Ozzello L, Ron Y, Pestka S. Injection of irradiated melanoma genetically modified to secrete IFN- α causes regression of an established tumor. Int J Oncol. 7:1995;17-24.
34. Rozera C, Mecchia M, Gresser I, Bandu M T, Proietti E, Venditti M, Sestili P, Santini S M, Fais S, Belardelli F, Ferrantini M. Murine IFN- α 1 gene transduced ESb tumor cells are rejected by host-mediated mechanisms despite resistance of the parental tumor to IFN- α / β therapy. Cancer Gene Ther. 6:1999;246-253.
35. Gresser I. The effect of interferon on experimental tumor metastases. Schirrmacher V, Schwartz-Albeiz R. Cancer Metastasis. 1989;171-180 Springer, Berlin.
36. +T cells and IFN- α / β Int J Cancer. 57:1994;538-543.
37. Dong Z, Juang S H, Kumar R, Eue I, Xie K, Bielenberg D, Lu W, Bucana C, Yang X, Fidler I. Suppression of tumorigenicity and metastasis in murine UV-2237 fibrosarcoma cells by infection with a retroviral vector harboring the interferon-beta gene. Cancer Immunol Immunother. 46:1998;137-146.
38. Rozera C, Carlei D, Lollini P L, De Giovanni C, Musiani P, Di Carlo E, Belardelli F, Ferrantini M. Interferon (IFN)- β gene transfer into TS/A adenocarcinoma cells and comparison with IFN-α . Differential effects on tumorigenicity and host response. Am J Pathol. 154:1999;1211-1222.
39. Singh R K, Gutman M, Bucana C D, Sanchez R, Llansa N, Fidler I J. Interferons α and β down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci USA. 92:1995;4562-4566.
40. Singh R K, Bucana C D, Gutman M, Fan D, Wilson M R, Fidler I J. Organ site-dependent expression of basic fibroblast growth factor in human renal cell carcinoma cells. Am J Pathol. 145:1994;365-374.
41. +T cells after injection of tumor cells expressing IFN- α 1 into syngeneic mice. Cancer Res. 58:1998;5795-5802.
42. Gansbacher B, Zier K, Cronin K, Hantzopoulos P A, Bouchard B, Houghton A, Gilboa E, Golde D. Retroviral gene transfer induced constitutive expression of interleukin-2 or interferon- γ in irradiated human melanoma cells. Blood. 80:1992;2817-2825.
43. Gastl G, Finstad C L, Guarini A, Bosl G, Gilboa E, Bander N H, Gansbacher B. Retroviral vector-mediated lymphokine gene transfer into human renal cancer cells. Cancer Res. 52:1992;6229-6236.
44. Ogasawara M, Rosenberg S A. Enhanced expression of HLA molecules and stimulation of autologous human tumor infiltrating lymphocytes following transduction of melanoma cells with γ -interferon genes. Cancer Res. 53:1993;3561-3568.
45. Traversari C, Meazza R, Coppolecchia M, Basso S, Verrecchia A, van der Bruggen P, Ardizzoni A, Gaggero A, Ferrini S. IFN- γ gene transfer restores HLA-class I expression and MAGE-3 antigen presentation to CTL in HLA-deficient small cell lung cancer. Gene Ther. 4:1997;1029-1035.
46. Belldegrun A, Tso C L, Sakata T, Duckett T, Brunda M J, Barsky S H, Chai J, Kaboo R, Lavey R S, McBride W H, deKernion J B. Human renal carcinoma line transfected with interleukin-2 and/or interferon alpha gene(s): implications for live cancer vaccines. J Natl Cancer Inst. 85:1993;207-216.
47. Zhang J F, Hu C, Geng Y, Blatt L M, Taylor M W. Gene therapy with an adeno-associated virus carrying an interferon gene results in tumor growth suppression and regression. Cancer Gene Ther. 3:1996;31-38.
48. Mecchia M, Matarrese P, Malorni W, D'Agostino G, Sestili P, Santini S M, Gauzzi M C, Venditti M, Mazzocchi A, Parmiani G, Belardelli F, Ferrantini M. Type I consensus Interferon (CIFN) gene transfer into human melanoma cells up-regulates p53 and enhances cisplatin-induced apoptosis: implications for new therapeutic strategies with IFN- α Gene Ther, 7:2000;167-179.
49. Sabaawy HM E, Ikehara S, Adachi Y, Quan S, Feldman E, Kancherla R, Abraham N G, Ahmed T. Enhancement of 5-fluorouracil cytotoxicity on human colon cancer cells by retrovirus-mediated interferon-α gene transfer. Int J Oncol. 14:1999;1143-1151.
50. D'Agostino G, Aricó E, Santodonato L, Venditti M, Sestili P, Masuelli L, Coletti A, Modesti A, Picchio G, Mosier D E, Ferrantini M, Belardelli F. Type I consensus IFN (IFN-con1) gene transfer into KSHV/HHV-8-infected BCBL-1 cells causes inhibition of viral lytic cycle activation via induction of apoptosis and abrogates tumorigenicity into SCID mice. J Interferon Cytokine Res. 19:1999;1305-1316.
51. Qin X Q, Tao N, Dergay A, Moy P, Fawell S, Davis A, Wilson J M, Barsoum J. Interferon- β gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice. Proc Natl Acad Sci USA. 95:1998;14411-14416.
52. Xu L, Xie K, Fidler I J. Therapy of human ovarian cancer by transfection with the murine interferon β gene: role of macrophage-inducible nitric oxide synthase. Hum Gene Ther. 9:1998;2699-2708.
53. Dong Z, Greene G, Pettaway C, Dinney CP N, Eue I, Lu W, Bucana C D, Balbay M D, Bielenberg D, Figler I J. Suppression of angiogenesis, tumorigenicity, and metastasis by human prostate cancer cells engineered to produce interferon- β Cancer Res. 59:1999;872-879.
54. Abdel-Wahab Z, Dar M M, Hester D, Vervaert C, Gangavalli R, Barber J, Darrow T L, Seigler H F. Effect of irradiation on cytokine production, MHC antigen expression, and vaccine potential of interleukin-2 and interferon- γ gene modified melanoma cells. Cell Immunol. 171:1996;246-254.
55. Nanni P, De Giovanni C, Landuzzi L, Nicoletti G, Frabetti F, Rossi I, Cavallo F, Giovarelli M, Forni G, Lollini P L. Therapy of murine mammary carcinoma metastasis with interferon γ and MHC gene-transduced tumour cells. Br J Cancer. 74:1996;1564-1569.
56. Allione A, Consalvo M, Nanni P, Lollini P L, Cavallo F, Giovarelli M, Forni G, Gulino A, Colombo M P, Dellabona P, Hock H, Blankestein T, Rosenthal F M, Gansbacher B, Bosco M C, Musso T, Gusella L, Forni G. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor α, granulocyte-macrophage colony-stimulating factor, and γ -interferon gene or admixed with conventional adjuvants. Cancer Res. 54:1994;6022-6026.
57. Miyatake S, Nishihara K, Kikuchi H, Yamashita J, Namba Y, Hanaoka M, Watanabe Y. Efficient tumor suppression by glioma-specific murine cytotoxic T lymphocytes transfected with interferon-γ gene. J Natl Cancer Inst. 82:1990;217-220.
58. +T cells against the wild-type tumor: correlation with antigen presentation capability. J Exp Med. 175:1992;1423-1431.
59. Shiloni E, Karp S E, Custer M C, Shilyansky J, Restifo N P, Rosenberg S A, Mulé J J. Retroviral transduction of interferon- γ cDNA into a nonimmunogenic murine fibrosarcoma: generation of T cells in draining lymph nodes capable of treating established parental metastatic tumor. Cancer Immunol Immunother. 37:1993;286-292.
60. Yang S, Vervaert C E, Seigler H F, Darrow T L. Tumor cells cotransduced with B7.1 and gamma-IFN induce effective rejection of established parental tumor. Gene Ther. 6:1999;253-262.
61. Tjuvajev J, Gansbacher B, Desai R, Beattie B, Kaplitt M, Matei C, Koutcher J, Gilboa E, Blasberg R. RG-2 glioma growth attenuation and severe brain edema caused by local production of interleukin-2 and interferon-γ Cancer Res. 55:1995;1902-1910.
62. Karavodin L M, Robbins J, Chong K, Hsu D, Ibanez C, Mento S, Jolly D, Fong T C. Generation of a systemic antitumor response with regional intratumoral injections of interferon γ retroviral vector. Hum Gene Ther. 9:1998;2231-2241.
63. Nomura T, Yasuda K, Yamada T, Okamoto S, Mahato R I, Watanabe Y, Takakura Y, Hashida M. Gene expression and antitumor effects following direct interferon (IFN)- γ gene transfer with naked plasmid DNA and DC-chol liposome complexes in mice. Gene Ther. 6:1999;121-129.
64. Ogura H, Tani K, Ozawa K, Nagata S, Asano S, Takaku F. Implantation of genetically manipulated fibroblasts into mice as antitumor α -interferon therapy. Cancer Res. 50:1990;5102-5106.
65. Rossi I, Nicoletti G, Landuzzi L, Frabetti F, De Giovanni C, Nanni P, Musiani P, Ferrantini M, Belardelli F, Lollini P L. Inhibition of lung colonisation of a mouse mammary carcinoma by therapeutic vaccination with interferon-α gene transduced tumor cells. Clin Exp Metastasis. 16:1998;123-128.
66. Hiroishi K, Tüting T, Tahara H, Lotze M T. Interferon-alpha gene therapy in combination with CD80 transduction reduces tumorigencity and growth of established tumor in poorly immunogenic tumor models. Gene Ther, 6:1999;1988-1994.
67. Zhang J F, Hu C, Geng Y, Selm J, Klein S B, Orazi A, Taylor M W. Treatment of a human breast cancer xenograft with an adenovirus vector containing an interferon gene results in rapid regression due to viral oncolysis and gene therapy. Proc Natl Acad Sci USA. 93:1996;4513-4518.
68. Coleman M, Muller S, Quezada A, Mendiratta S K, Wang J, Thull N M, Bishop J, Matar M, Mester J, Pericle F. Nonviral interferon α gene therapy inhibits growth of established tumors by eliciting a systemic immune response. Hum Gene Ther. 9:1998;2223-2230.
69. Yagi K, Ohishi N, Hamada A, Shamoto M, Ohbayashi M, Ishida N, Nagata A, Kanazawa S, Nishikimi M. Basic study on gene therapy of human malignant glioma by use of the cationic multilamellar liposome-entrapped human interferon beta gene. Hum Gene Ther. 10:1999;1975-1982.
70. Horton H M, Hernandez P, Parker S E, Barnhart K M. Anti-tumor effects of interferon-omega: in vivo therapy of human tumor xenografts in nude mice. Cancer Res. 59:1999;4064-4068.
71. Horton H M, Anderson D, Hernandez P, Barnhart K M, Norman J A, Parker S E. A gene therapy for cancer using intramuscular injection of plasmid DNA encoding interferon α Proc Natl Acad Sci USA. 96:1999;1553-1558.
72. Cao X, Wang J, Zhang W, Chen G, Kong X, Tani K. Treatment of human hepatocellular carcinoma by fibroblast-mediated human interferon α gene therapy in combination with adoptive chemoimmunotherapy. J Cancer Res Clin Oncol. 121:1995;457-462.
73. Wang J, Cao X, Zhang W, Ye T, Tani K. Treatment of leukemia with fibroblast-mediated interferon-alpha gene therapy alone or in combination with doxorubicin. Leukemia Res. 20:1996;379-384.
74. Santodonato L, Ferrantini M, Gabriele L, Proietti E, Venditti M, Musiani P, Modesti A, Modica A, Lupton S D, Belardelli F. Cure of mice with established metastatic Friend leukemia cell tumors by a combined therapy with tumor cells expressing both interferon- α 1 and Herpes simplex thymidine kinase followed by ganciclovir. Hum Gene Ther. 7:1996;1-10.
75. Santodonato L, D'Agostino G, Santini S M, Carlei D, Musiani P, Modesti A, Signorelli P, Belardelli F, Ferrantini M. Local and systemic antitumor response after combined therapy of mouse metastatic tumors with tumor cells expressing IFN-α and HSVtk: perspectives for the generation of cancer vaccines. Gene Ther. 4:1997;1246-1255.
76. Nanni P, De Giovanni C, Nicoletti G, Landuzzi L, Rossi I, Frabetti F, Giovarelli M, Forni G, Cavallo F, Di Carlo E, Musiani P, Lollini P L. The immune response elicited by mammary adenocarcinoma cells transduced with interferon- γ and cytosine deaminase genes cures lung metastases by parental cells. Hum Gene Ther. 9:1998;217-224.
77. Wang Z H, Zagzag D, Zeng B, Kolodny E H. In vivo and in vitro glioma cell killing induced by an adenovirus expressing both cytosine deaminase and thymidine kinase and its association with interferon- α J Neuropathol Exp Neurol. 58:1999;847-858.
78. Taniguchi K, Petersson M, Hoglund P, Kiessling R, Klein G, Karre K. Interferon γ induces lung colonization by intravenously inoculated B16 melanoma cells in parallel with enhanced expression of class I major histocompatibility complex antigens. Proc Natl Acad Sci USA. 84:1987;3405-3409.
79. Lollini P L, De Giovanni C, Del Re B, Nicoletti G, Prodi G, Nanni P. Interferon-mediated enhancement of metastasis. Are MHC antigens involved? Clin Exp Metastatis. 5:1987;277-287.
80. Kelly S A, Gschmeissner S, East N, Balkwill F R. Enhancement of metastatic potential by gamma-interferon. Cancer Res. 51:1991;4020-4027.
81. Finkelman F D, Svetic A, Gresser I, Snapper C, Holmes J, Trotta P P, Katona I M, Gause W C. Regulation by interferon α of immunoglobulin isotype selection and lymphokine production in mice. J Exp Med. 174:1991;1179-1188.
82. Romagnani S. Induction of TH1 and TH2 responses: a key role for the 'natural' immune response? Immunol Today. 13:1992;379-381.
83. Rogge L, Barberis-Maino L, Biffi M, Passini N, Presky D H, Gubler U, Sinigaglia F. Selective expression of an Interleukin-12 receptor component by human T helper 1 cells. J Exp Med. 485:1997;825-830.
84. von Hoegen P. Synergistic role of type I interferons in the induction of protective cytotoxic T lymphocytes. Immunol Lett. 47:1995;157-162.
85. Muller U, Steinhoff U, Reis LF L, Hemni S, Pavlovic J, Zinkernagel R M, Aguet M. Functional role of type I and type II interferons in antiviral defense. Science. 264:1994;1918-1921.
86. Chen L K, Mathieu-Mahul D, Bach F H, Dausset J, Bensussan A, Sasportes M. Recombinant interferon alpha can induce rearrangement of T-cell antigen receptor alpha-chain genes and maturation to cytotoxicity in T-lymphocyte clones in vitro. Proc Natl Acad Sci USA. 83:1986;4887-4889.
87. Tüting T, Wilson C C, Martin D M, Kasamon Y L, Rowles J, Ma D I, Slingluff C L Jr, Wagner S N, van der Bruggen P, Baar J, Lotze M T, Storkus W J. Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-α J Immunol. 160:1998;1139-1147.
88. Vieillard V, Cremer I, Lauret E, Rozenbaum W, Debre P, Autran B, De Maeyer E. Interferon beta transduction of peripheral blood lymphocytes from HIV-infected donors increases Th-1 type cytokine production and improves the proliferative response to recall antigens. Proc Natl Acad Sci USA. 94:1997;11595-11600.
89. Wilson C C, Olson W C, Tüting T, Rinaldo C R, Lotze M T, Storkus W J. HIV-1-specific CTL responses primed in vitro by blood-derived dendritic cells and Th1-biasing cytokines. J Immunol. 162:1999;3070-3078.
90. Tough D F, Borrow P, Sprent J. Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science. 272:1996;1947-1950.
91. Sun S, Zhang X, Tough D F, Sprent J. Type I interferon-mediated stimulation of T cells by CpG DNA. J Exp Med. 188:1998;2335-2342.
92. Marrack P, Kappler J, Mitchell T. Type I interferons keep activated T cells alive. J Exp Med. 189:1999;531-530.
93. Matikainen S, Sareneva T, Ronni T, Lehtonen A, Koskinen P J, Julkunen I. Interferon- α activates multiple STAT proteins and upregulates proliferation-associated IL-2Rα , c-myc, and pim-1 genes in human T cells. Blood. 93:1999;1980-1991.
94. Luft T, Pang K C, Thomas E, Hertzog P, Hart DN J, Trapani J, Cebon J. Type I IFNs enhance the terminal differentiation of dendritic cells. J Immunol. 161:1998;1947-1953.
95. Paquette R L, Hsu N C, Kiertscher S M, Park A N, Tran L, Roth M D, Gaspy J A. Interferon- α and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells. J Leuk Biol. 64:1998;358-367.
96. Albert M L, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature. 392:1998;86-89.
97. Siegal F P, Kadowaki N, Shodell M, Fitzgerald-Bocarsly P A, Shah K, Ho S, Antonenko S, Liu Y J. The nature of the principal type I interferon-producing cells in human blood. Science. 284:1999;1835-1837.
98. Hagmann M. Elusive interferon α producers nailed down. Science. 284:1999;1746.
99. Belardelli F, Vignaux F, Proietti E, Gresser I. Injection of mice with antibody to interferon renders peritoneal macrophages permissive for vesicular stomatitis virus and encephalomyocarditis virus. Proc Natl Acad Sci USA. 81:1984;602-606.
100. +T cells from virus-induced depletion in SCID mice transplanted with human cells. Virology. 263:1999;78-88.
101. Gresser I, Belardelli F, Maury C, Maunoury M T, Tovey M G. Injection of mice with antibody to interferon enhances the growth of transplantable murine tumors. J Exp Med. 158:1983;2095-2107.